Related Experiment Videos
3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists.
M G Russell1, V G Matassa, R R Pengilley
1Merck Sharp & Dohme Research Laboratories, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, U.K.
Journal of Medicinal Chemistry
|December 10, 1999
Summary
Researchers developed a selective serotonin 5-HT(1D) receptor agonist, L-772,405, for potential migraine treatment. This compound shows high affinity and selectivity, offering a promising new avenue for fewer side effects.
Area of Science:
- Pharmacology
- Medicinal Chemistry
- Neuroscience
Background:
- Migraine treatments often target serotonin receptors.
- Existing 5-HT(1D/1B) receptor agonists are entering the market.
- Need for agents with improved selectivity and reduced side effects.
Purpose of the Study:
- To develop selective human serotonin 5-HT(1D) receptor agonists.
- To identify potential antimigraine agents with fewer side effects.
- To investigate compounds for their efficacy in migraine treatment.
Main Methods:
- Synthesis of a series of 3-[3-(piperidin-1-yl)propyl]indoles.
- Identification and characterization of compound 80 (L-772,405).
- Evaluation of receptor binding affinity, selectivity, and bioavailability.
Main Results:
- L-772,405 identified as a high-affinity h5-HT(1D) receptor full agonist.
- Demonstrated 170-fold selectivity for h5-HT(1D) over h5-HT(1B) receptors.
- Exhibited excellent selectivity against other receptors and good bioavailability in rats.
Conclusions:
- L-772,405 is a potent and selective h5-HT(1D) receptor agonist.
- Represents a valuable pharmacological tool for studying migraine.
- Potential for development into a novel antimigraine therapeutic with improved safety profile.